Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
4,766
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,775.00 | 4.40 | 0.05% |
CAC 40 | 7,742.24 | 57.56 | 0.75% |
DAX 40 | 23,699.12 | 182.89 | 0.78% |
Dow JONES (US) | 42,466.07 | 268.28 | 0.64% |
FTSE 100 | 8,875.22 | 24.59 | 0.28% |
HKSE | 24,060.99 | 168.43 | 0.70% |
NASDAQ | 19,694.37 | 287.54 | 1.48% |
Nikkei 225 | 38,311.33 | 477.08 | 1.26% |
NZX 50 Index | 12,690.13 | 137.26 | 1.09% |
S&P 500 | 6,027.58 | 50.61 | 0.85% |
S&P/ASX 200 | 8,548.40 | 1.00 | 0.01% |
SSE Composite Index | 3,388.73 | 11.73 | 0.35% |